March 22, 2016 | Harvard just got $20 million in cash from Merck. Surely, some industry haters will spit out their coffee over that headline. To those in academia who see their endeavor as that of purely noble truth-seekers and educators, striking a lucrative deal with pharma is tantamount to doing business with Tony Soprano. Forbes